TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

BEIGENE

OncologyGastroenterologyImmunology
Biotech

BEIGENE is a biotechnology company focused on Oncology, Gastroenterology, Immunology.

2024
Since
1
Drugs
-
Trials
14
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

TEVIMBRA 2025-12-09
Efficacy
TEVIMBRA 2025-12-09
Efficacy
TEVIMBRA 2025-12-09
Efficacy
TEVIMBRA 2025-12-02
Labeling
TEVIMBRA 2025-05-01
Labeling
TEVIMBRA 2025-04-22
Efficacy
TEVIMBRA 2025-04-22
Efficacy
TEVIMBRA 2025-04-22
Efficacy
TEVIMBRA 2025-04-22
Efficacy
TEVIMBRA 2025-04-22
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 89%
1 drugs Phase 3: 22 Phase 2: 36 Phase 1: 46
Gastroenterology 8%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 5
Immunology 2%
0 drugs Phase 2: 2 Phase 1: 1
Respiratory 1%
0 drugs Phase 2: 1
Dermatology 0%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Dermatology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Respiratory
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology, Respiratory
MALLINCKRODT specialty
Gastroenterology, Dermatology, Immunology, Respiratory
GSK big-pharma
Respiratory, Oncology, Immunology